Search

Your search keyword '"Driesen, Michele"' showing total 5 results
Start Over Author "Driesen, Michele"
5 results on '"Driesen, Michele"'

1. Combined Phylogeographic Analyses and Epidemiologic Contact Tracing to Characterize Atypically Pathogenic Avian Influenza (H3N1) Epidemic, Belgium, 2019

Author

Van Borm, Steven, Boseret, Geraldine, Dellicour, Simon, Steensels, Mieke, Roupie, Virginie, Vandenbussche, Frank, Mathijs, Elisabeth, Vilain, Aline, Driesen, Michele, Dispas, Marc, Delcloo, Andy W., Lemey, Philippe, Mertens, Ingeborg, Gilbert, Marius, Lambrecht, Benedicte, and van den Berg, Thierry

Subjects
Identification and classification, Distribution, Genetic aspects, Research, Methods, Causes of, Company distribution practices, Viral research, Epidemics -- Causes of -- Distribution, Avian influenza -- Causes of -- Distribution, Phylogeny -- Research, Avian influenza viruses -- Identification and classification -- Distribution -- Genetic aspects, Contact tracing -- Methods, Virus research
Abstract

Wild birds in the orders Anseriformes and Charadriiformes are considered natural reservoirs of avian influenza viruses (AIVs; family Orthomyxoviridae), maintaining the 16 hemagglutinin (H1-16) and 9 neuraminidase (N1-9) viral subtypes [...]

Published
2023
Full Text
View/download PDF

2. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study

Author

Zignol, Matteo, Cabibbe, Andrea Maurizio, Dean, Anna S, Glaziou, Philippe, Alikhanova, Natavan, Ama, Cecilia, Andres, Sönke, Barbova, Anna, Borbe-Reyes, Angeli, Chin, Daniel P, Cirillo, Daniela Maria, Colvin, Charlotte, Dadu, Andrei, Dreyer, Andries, Driesen, Michèle, Gilpin, Christopher, Hasan, Rumina, Hasan, Zahra, Hoffner, Sven, Hussain, Alamdar, Ismail, Nazir, Kamal, S M Mostofa, Khanzada, Faisal Masood, Kimerling, Michael, Kohl, Thomas Andreas, Mansjö, Mikael, Miotto, Paolo, Mukadi, Ya Diul, Mvusi, Lindiwe, Niemann, Stefan, Omar, Shaheed V, Rigouts, Leen, Schito, Marco, Sela, Ivita, Seyfaddinova, Mehriban, Skenders, Girts, Skrahina, Alena, Tahseen, Sabira, Wells, William A, Zhurilo, Alexander, Weyer, Karin, Floyd, Katherine, and Raviglione, Mario C

Published
2018
Full Text
View/download PDF

4. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project

Author

Zignol, Matteo, Dean, Anna S, Alikhanova, Natavan, Andres, Sönke, Cabibbe, Andrea Maurizio, Cirillo, Daniela Maria, Dadu, Andrei, Dreyer, Andries, Driesen, Michèle, Gilpin, Christopher, Hasan, Rumina, Hasan, Zahra, Hoffner, Sven, Husain, Ashaque, Hussain, Alamdar, Ismail, Nazir, Kamal, Mostofa, Mansjö, Mikael, Mvusi, Lindiwe, Niemann, Stefan, Omar, Shaheed V, Qadeer, Ejaz, Rigouts, Leen, Ruesch-Gerdes, Sabine, Schito, Marco, Seyfaddinova, Mehriban, Skrahina, Alena, Tahseen, Sabira, Wells, William A, Mukadi, Ya Diul, Kimerling, Michael, Floyd, Katherine, Weyer, Karin, and Raviglione, Mario C

Published
2016
Full Text
View/download PDF

5. Re-evaluation of Critical Concentrations of Antituberculosis Fluoroquinolones in the Mycobacteria Growth Indicator Tube 960 System.

Author

Rupasinghe, Praharshinie, Driesen, Michele, Vereecken, Jens, de Jong, Bouke, and Rigouts, Leen

Abstract

Background: Fluoroquinolones (FQs) have substantial activity against the Mycobacterium tuberculosis complex (MTBc) by preventing bacterial DNA synthesis through DNA gyrase inhibition. The reference standard for FQ-resistance testing is phenotypic drug-susceptibility testing (pDST) based on growth inhibition of MTBc in drug-containing Mycobacteria Growth Indicator Tube system (MGIT) media at a critical concentration (CC) that differentiates phenotypically wild-type from nonwild-type MTBc and at a clinical breakpoint that identifies strains that will likely still respond to treatment at higher doses. Despite the recent introduction of powerful new TB drugs, highly sensitive detection of clinically defined FQ resistance remains key. Method: In this study, we re-evaluated the current WHO-recommended CCs of Lfx (1.0 mg/ml), Mfx (0.25 mg/ml), Gfx (0.25 µg/ml), and the nowadays, obsolete CC of Ofx (2.0 mg/ml) for MGIT, using 147 MTBc isolates with known gyrA and gyrB sequences including both high-and low-level FQ resistance-conferring mutants. We tested a wide range of drug concentrations covering the current and former/obsolete WHO-recommended CCs for FQs and some intermediate concentrations to challenge the current WHO-recommended CCs. Results: The specificity of all four CCs was 100%. The sensitivities varied: 92.4% for Ofx and Lfx, 85.7% for Mfx, and 83.2% for Gfx. Lowering the CC of Mfx to 0.125 mg/ml would allow to correctly classify all wild-type and mutant isolates while lowering the CC of Gfx to 0.125 mg/ml would still misclassify some gyrA/gyrB mutants as susceptible. Conclusion: Based on our findings, a minimal inhibitory concentration of 0.125 mg/ml on MGIT medium is a more appropriate CC for Mfx and probably also as a surrogate for overall FQ resistance in the MTBc. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results